Posted inClinical Updates Rheumatology
Targeting FcRn to Combat Systemic Sclerosis: Promising Preclinical Advances with Efgartigimod
Pharmaceutical blockade of the neonatal Fc receptor (FcRn) using efgartigimod reduces autoantibody-driven inflammation and fibrosis in a mouse model of systemic sclerosis, highlighting a potential disease-modifying strategy.
